BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15846469)

  • 1. Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2).
    Kondo C; Onuki R; Kusuhara H; Suzuki H; Suzuki M; Okudaira N; Kojima M; Ishiwata K; Jonker JW; Sugiyama Y
    Pharm Res; 2005 Apr; 22(4):613-8. PubMed ID: 15846469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine.
    Okudaira N; Komiya I; Sugiyama Y
    J Pharmacol Exp Ther; 2000 Nov; 295(2):717-23. PubMed ID: 11046110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug.
    Okudaira N; Tatebayashi T; Speirs GC; Komiya I; Sugiyama Y
    J Pharmacol Exp Ther; 2000 Aug; 294(2):580-7. PubMed ID: 10900235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
    Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
    Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
    Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
    Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
    Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides.
    Sesink AL; Arts IC; de Boer VC; Breedveld P; Schellens JH; Hollman PC; Russel FG
    Mol Pharmacol; 2005 Jun; 67(6):1999-2006. PubMed ID: 15749994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.
    Merino G; Alvarez AI; Pulido MM; Molina AJ; Schinkel AH; Prieto JG
    Drug Metab Dispos; 2006 Apr; 34(4):690-5. PubMed ID: 16434544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
    Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
    Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
    Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
    Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
    Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
    Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
    Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
    Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
    An G; Gallegos J; Morris ME
    Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice.
    Alfaras I; Pérez M; Juan ME; Merino G; Prieto JG; Planas JM; Alvarez AI
    J Agric Food Chem; 2010 Apr; 58(7):4523-8. PubMed ID: 20232796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.